Patient Support Center

Yes, 66.3% of patients in the multi-center clinical study kept at least 50% of their hair. Typically, patients will start to see shedding (overall thinning ...

66.3% of patients using DigniCap in the multi-center clinical study kept at least 50% of their hair.

No. DigniCap prevents hair loss on the scalp area, where cooling is applied and therefore does not prevent eyebrow or eyelashes from thinning.

Cooling of the scalp is a proven approach to reduce chemotherapy-induced hair loss that has been used successfully by thousands of patients worldwide with ...

Scalp cooling has been evaluated mainly with regimens including anthracyclines (such as doxorubicin and epirubicin) and taxanes (such as paclitaxel and docet...

No. Scalp metastases is the development of secondary malignancy at a site away from the primary cancer growth. Scalp cooling does not increase this risk, ...